On the cytotoxicity of chiral ruthenium complexes containing sulfur amino acids against breast tumor cells (MDA-231 and MCF-7)

dc.creatorLeite, Celisnolia Morais
dc.creatorAraujo Neto, João Honorato de
dc.creatorCorrea, Rodrigo de Souza
dc.creatorVegas, Legna Andreina Colina
dc.creatorMartínez Otero, Diego
dc.creatorMartins, Paulo Roberto
dc.creatorSilva, Cristiane Garcia
dc.creatorBatista, Alzir Azevedo
dc.date.accessioned2024-07-18T14:48:22Z
dc.date.available2024-07-18T14:48:22Z
dc.date.issued2021
dc.description.abstractBackground: Breast cancer is one of the most common types among women. Its incidence progressively increases with age, especially after age 50. Platinum compounds are not efficient in the treatment of breast cancer, highlighting the use of other metals for the development of new chemotherapeutic agents. Objective: This paper aims to obtain three new ruthenium compounds that incorporate sulfur amino acids in their structures and to investigate their cytotoxic activity in breast tumor cell lines. Methods: Complexes with general formula [Ru(AA)(dppb)(bipy)] (complexes 1 and 2) or [Ru(AA)(dppb) (bipy)]PF6 (complex 3), where AA = L-cysteinate (1), D-penicillaminate (2), and L-deoxyalliinate (3), dppb = 1,4-bis(diphenylphosphino)butane and 2,2´-bipyridine, were obtained from the cis-[RuCl2(dppb)(bipy)] precursor. The cytotoxicity of the complexes on MDA-MB-231 (triple negative human breast cancer); MCF-7 (double positive human breast cancer) and V79 (hamster lung fibroblast) was performed by the MTT (4,5- dimethylthiazol-2-yl-2,5-diphenyltetrazolium bromide) method. The control agent was the cisplatin, which is a commercially available drug for cancer treatment. Results: In complexes (1) and (2), the ligands are coordinated to the metal center by nitrogen and sulfur atoms, while in complex (3), coordination is through the oxygen and nitrogen atoms. These suggestions are based on the infrared and 31P{1H} NMR data. For complexes (1) and (2), their X-ray structures were determined confirming this suggestion. The three complexes are stable in a mixture of DMSO (80%) and biological medium (20%) for at least 48h and presented cytotoxicity against the MDA-MB-231 and MCF-7 tumor cells with reasonable selectivity indexes. Conclusion: Our work demonstrated that ruthenium complexes containing sulfur amino acids, bipyridines and bisphosphines showed cytotoxicity against the MDA-MB-231 and MCF-7 cancer cell lines, in vitro, and that they interact weakly with the DNA (Deoxyribonucleic Acid) and the HSA (Human Serum Albumin) biomolecules.
dc.identifier.citationLEITE, Celisnolia M. et al. On the cytotoxicity of chiral ruthenium complexes containing sulfur amino acids against breast tumor cells (MDA-231 and MCF-7). Anti-Cancer Agents in Medicinal Chemistry, [s. l.], v. 21, n. 9, p. 1172-1182, 2021. DOI: 10.2174/1871520620666200824114816. Disponível em: https://www.eurekaselect.com/article/109446. Acesso em: 5 jul. 2024.
dc.identifier.doi10.2174/1871520620666200824114816
dc.identifier.issn1871-5206
dc.identifier.issne- 1875-5992
dc.identifier.urihttps://www.eurekaselect.com/article/109446
dc.language.isoeng
dc.publisher.countryHolanda
dc.publisher.departmentInstituto de Química - IQ (RMG)
dc.rightsAcesso Restrito
dc.subjectRu(II)/amino acid complexes
dc.subjectDiastereoisomers
dc.subjectBreast cancer cells (MDA-MB-231 and MCF-7)
dc.subjectCytotoxicity
dc.subjectDNA and HSA interaction
dc.subjectDNA docking
dc.titleOn the cytotoxicity of chiral ruthenium complexes containing sulfur amino acids against breast tumor cells (MDA-231 and MCF-7)
dc.typeArtigo

Arquivos

Licença do Pacote

Agora exibindo 1 - 1 de 1
Carregando...
Imagem de Miniatura
Nome:
license.txt
Tamanho:
1.71 KB
Formato:
Item-specific license agreed upon to submission
Descrição: